Harpoon Therapeutics, Inc. announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, 2022. Dr. Sacks will serve as a consultant to Harpoon through the end of the year. While the executive search for a new Chief Medical Officer is ongoing, Yifah Yaron, M.D., Ph.D., and Mark Sayles, M.D., Ph.D., both Medical Team Leaders, will continue to advance the Company's clinical programs, HPN328 and HPN217, and direct clinical activities for the entire portfolio.
Harpoon Therapeutics, Inc.
Equities
HARP
US41358P2056
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |